[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
A new antitumor agent, UFT, was administered to one patient with endometrial cancer and one with ovarian cancer. Case 1:53 year-old female with advanced endometrial cancer with an invasion to the bladder. Histological diagnosis was endometrial carcinoma. UFT of 600 mg per day was administered orally daily for 28 days as one course. Palpable inguinal lymph nodes and suprapubic uterus mass were disappeared by one course of UFT. Case 2:50 year-old female with recurrent ovarian cancer invading to the rectum and uterus with a histological diagnosis of papillary tubular adenocarcinoma. One course of UFT produced 64% decrease in the pelvic tumor size, and additional one course 74% decrease. No marked side effects except stomatitis in case 1 were noticed during UFT administration. Although, unfortunately, these two patients died of ileus due to cancer, marked antitumor effects of UFT on endometrial cancer and ovarian cancer were elucidated.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage*; D014498:Uracil / Q000008:administration & dosage*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004338:Drug Combinations; D005641:Tegafur; D014498:Uracil; D005472:Fluorouracil